Neoantigens Market Global Analsyis and Forecast 2028
The neoantigens market was valued at US$ 2,71,428.57 thousand in 2023, and it is projected to reach US$ 10,54,783.54 thousand by 2028; it is expected to grow at a CAGR of 31.2% from 2023 to 2028.
Neoantigens are recently developed antigens that have not been detected by the immune system historically. Alterations in tumor proteins may result in the development of neoantigens caused by mutations or viral proteins. Neoantigens are used in selective treatments for cancerous cells.
The neoantigens market is segmented based on treatment, therapeutic specialty, and geography. Based on geography, the market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South and Central America. The report offers insights and in-depth analysis of the neoantigens market emphasizing on various parameters such as market trends, technological advancements, market dynamics, and competitive landscape analysis of leading market players across the world. It also includes COVID-19 impact analysis across all the regions. It is estimated that the market is likely to have a steady growth rate during the forecast period.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Neoantigens Market: Strategic Insights
Market Size Value in US$ 2,71,428.57 thousand in 2023 Market Size Value by US$ 10,54,783.54 thousand by 2028 Growth rate CAGR of 31.2% from 2023-2028 Forecast Period 2023-2028 Base Year 2023
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Neoantigens Market: Strategic Insights
| Market Size Value in | US$ 2,71,428.57 thousand in 2023 |
| Market Size Value by | US$ 10,54,783.54 thousand by 2028 |
| Growth rate | CAGR of 31.2% from 2023-2028 |
| Forecast Period | 2023-2028 |
| Base Year | 2023 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Market Insights
Developments in Neoantigen Vaccines Against Cancer
Developments in biotechnology have led to rise in acceptance for immunotherapy, further driving its use in personalized medicines. Immunotherapy is widely used to treat cancer; a few the immunotherapy procedures involve the use of neoantigens, the antigens present on the surface of cancer cells. Therefore, applications of neoantigens are being widely studied to treat cancer. The uniqueness of neoantigens allows researchers to identify patients’ immune system and find antigens to target cancer cells without disturbing healthy cells.
The developments in immunotherapy caught pace after 2015, when the first clinical trial of neoantigen vaccine was performed. In 2017, two additional clinical trial studies were published by Neon Therapeutics that proved the efficacy of neoantigen vaccine treat melanoma (skin cancer) in humans. The positive results of clinical trials have attracted various startups to discover and develop neoantigen-based cancer therapeutics. Many companies have shown interest in the development of neoantigens. Following are few examples of companies involved in the development of neoantigens.
- BioNTech SE is a German company operating in the neoantigen vaccines market. BioNTech SE has developed Individualized Vaccines Against Cancer (IVAC) Mutanome platform that engineer RNA molecules to produce customized neoantigen vaccine. The clinical trials for IVAC that target triple negative breast cancer, multiple tumor types, and melanoma are pending.
- The ATLAS platform of Genocea Biosciences uses an ex-vivo method to develop neoantigen vaccines. Genocea Biosciences has raised ~US$ 91 million funds from investors such as Polaris Partners, GlaxoSmithKline, and Johnson & Johnson Innovation to develop its neoantigen cancer vaccine—GEN-009. Currently in the Phase 1a/2 clinical trial, the vaccine is designed to treat melanoma, lung cancer, and carcinomas.
- Gritstone Oncology uses its AI platform—EDGE—to develop neoantigen vaccines using an in-silico approach. The company has developed two products GRANITE-001 and SLATE-001. GRANITE-001 is designed as an individual treatment based on patient’s specific tumor type, whereas SLATE-001 is formulated as a common neoantigen vaccine that can be used for multiple patients showing similar neoantigen.
- Agenus Inc. has developed AutoSynVax (ASV) neoantigen vaccine that is administered with an adjuvant QS-21 Stimulon to treat solid tumors. At present ASV is in the Phase 1 clinical trial in USA.
- Since 2016, Moderna, Inc. is involved in clinical trials for its personalized cancer vaccine (PCV) mRNA-4157 in combination with Keytruda by Merck. In November 2020, Moderna, Inc. published updates about its cancer vaccines stating that administrating mRNA-4157 in combination with Keytruda is well tolerated at all dose levels and has produced responses in patients.
Such developments in the neoantigen vaccines against cancer are fuelling the market growth.
Treatment-Based Insights
Based on treatment, the neoantigens market is segmented into combination therapy and mono therapy. In 2023, the combination therapy segment is estimated to have a larger share of the market. However, the mono therapy segment is expected to have a faster growth during the forecast period.
Therapeutic Specialty -Based Insights
Based on therapeutic specialty, the neoantigens market is segmented into gastrointestinal cancer, lung cancer, solid tumor, urinary systems cancers, melanoma, head and neck cancer, and others. In 2023, the gastrointestinal cancer segment is estimated to hold the largest share of the market and is expected to grow at the fastest rate in the coming years.
Inorganic strategies were highly adopted by the market players to meet the changing customer demand and maintain their improved services. For instance, in January 2021, Genocea Announces Cancer Discovery Publication owing to the benefits of neoantigen identification using the ATLAS Platform. This discovery strengthens neoantigen immunotherapies by theoretically ensuring that they target the correct neoantigens while removing Inhibigens.
Neoantigens Market Report Scope
By Treatment
- Combination Therapy
- Mono Therapy
By Therapeutic Specialty
- Gastrointestinal Cancer
- Lung Cancer
- Solid Tumors
- Urinary System Cancers
- Melanoma
- Head and Neck Cancer
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Europe
- France
- Germany
- Italy
- UK
- Spain
- Rest of Europe
- Asia Pacific (APAC)
- China
- India
- South Korea
- Japan
- Australia
- Rest of APAC
- Middle East & Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Rest of MEA
- South and Central America (SCAM)
- Brazil
- Argentina
- Rest of SCAM
Company Profiles
- Achilles Therapeutics plc
- Advaxis, Inc.
- Frame Cancer Therapeutics
- Genocea, Gradalis, Inc.
- Gritstone Oncology
- Immunicum AB
- Medigene AG
- Ziopharm Oncology, Inc.
- Moderna, Inc.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Treatment and Therapeutic Specialty
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
Several companies into clinical trial phases for their respective neoantigens. It is expected that by 2023, companies will commercialize their products in the market. In addition, it is expected that the cost of neoantigens will be much higher than cancer vaccines.
Key factors that are driving growth of the market are developments in neoantigen vaccines against cancer and increasing prevalence of cancer. However, possible side effects associated with neoantigen vaccines are likely to hinder the growth of the neoantigens market.
Neoantigens are recently developed antigens that have not been detected by the immune system historically. Alterations in tumor proteins may result in the development of neoantigens caused by mutations or viral proteins. Neoantigens are used in selective treatments for cancerous cells.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Neoantigens Market – By Treatment
1.3.2 Neoantigens Market – By Therapeutic Specialty
1.3.3 Neoantigens Market– By Geography
2. Neoantigens Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Neoantigens Market– Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.4 Middle East and Africa PEST Analysis
4.2.5 South and Central America PEST Analysis
4.3 Expert Opinion
5. Neoantigens Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Developments in Neoantigen Vaccines Against Cancer
5.1.2 Increasing Prevalence of Cancer
5.2 Market Restraints
5.2.1 Possible Side Effects Associated with Neoantigen Vaccines
5.3 Market Opportunities
5.3.1 Application of Next-generation Sequencing for Neoantigen Identification
5.4 Future Trends
5.4.1 Use of AI in Neoantigen Vaccine Development
5.5 Impact Analysis
6. Neoantigens Market – Global Analysis
6.1 Global Neoantigens Market Revenue Forecast and Analysis
6.2 Global Neoantigens Market, By Geography - Forecast and Analysis
6.3 Key Players
7. Neoantigens Market Analysis – By Treatment
7.1 Overview
7.2 Neoantigens Market Revenue Share, by Treatment (2023 and 2028)
7.3 Combination Therapy
7.3.1 Overview
7.3.2 Combination Therapy: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)
7.4 Mono Therapy
7.4.1 Overview
7.4.2 Mono Therapy: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)
8. Neoantigens Market Analysis – By Therapeutic Specialty
8.1 Overview
8.2 Neoantigens Market Revenue Share, by Therapeutic Specialty (2023 and 2028)
8.3 Gastrointestinal Cancer
8.3.1 Overview
8.3.2 Gastrointestinal Cancer: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)
8.4 Lung Cancer
8.4.1 Overview
8.4.2 Lung Cancer: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)
8.5 Solid Tumors
8.5.1 Overview
8.5.2 Solid Tumors: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)
8.6 Urinary System Cancers
8.6.1 Overview
8.6.2 Urinary System Cancers: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)
8.7 Melanoma
8.7.1 Overview
8.7.2 Melanoma: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)
8.8 Head and Neck Cancers
8.8.1 Overview
8.8.2 Head and Neck Cancers: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)
8.9 Others
8.9.1 Overview
8.9.2 Others: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)
9. Neoantigens Market – Geographical Analysis
9.1 North America: Neoantigens Market Revenue and Forecast to 2028
9.1.1 Overview
9.1.2 North America: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.1.3 North America: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)
9.1.4 North America: Neoantigens Market, by Therapeutic Specialty, 2023–2028 (USD Thousand)
9.1.5 North America: Neoantigens Market, by Country, 2023 & 2028 (%)
9.1.6 US: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.1.6.1 US: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.1.6.2 US: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)
9.1.6.3 US: Neoantigens Market, by Therapeutic Specialty, 2023–2028 (USD Thousand)
9.1.7 Canada: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.1.7.1 Canada: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.1.7.2 Canada: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)
9.1.7.3 Canada: Neoantigens Market, by Therapeutic Specialty, 2023–2028 (USD Thousand)
9.1.8 Mexico: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.1.8.1 Mexico: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.1.8.2 Mexico: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)
9.1.8.3 Mexico: Neoantigens Market, by Therapeutic Specialty, 2023–2028 (USD Thousand)
9.2 Europe: Neoantigens Market
9.2.1 Overview
9.2.2 Europe: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.2.3 Europe: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
9.2.4 Europe: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)
9.2.5 Europe: Neoantigens Market, by Country, 2023 & 2028(%)
9.2.6 Germany: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.2.6.1 Germany: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.2.6.2 Germany: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
9.2.6.3 Germany: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)
9.2.7 France: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.2.7.1 France: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.2.7.2 France: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
9.2.7.3 France: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)
9.2.8 UK: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.2.8.1 UK: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.2.8.2 UK: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
9.2.8.3 UK: Neoantigens Market, Application – Revenue and Forecast to 2028 (USD Thousand)
9.2.9 Italy: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.2.9.1 Italy: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.2.9.2 Italy: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
9.2.9.3 Italy: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)
9.2.10 Spain: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.2.10.1 Spain: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.2.10.2 Spain: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
9.2.10.3 Spain: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)
9.2.11 Rest of Europe: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.2.11.1 Rest of Europe: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.2.11.2 Rest of Europe: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
9.2.11.3 Rest of Europe: Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)
9.3 Asia Pacific: Neoantigens Market
9.3.1 Overview
9.3.2 Asia Pacific: Neoantigens Market - Revenue and Forecast to 2028 (USD Thousand)
9.3.3 Asia Pacific: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)
9.3.4 Asia Pacific: Neoantigens Market, by Therapeutic Application – 2023–2028 (USD Thousand)
9.3.5 Asia Pacific: Neoantigens Market, by Country, 2023 & 2028 (%)
9.3.6 China: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.3.6.1 China: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.3.6.2 China: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)
9.3.6.3 China: Neoantigens Market, by Therapeutic Application, 2023–2028 (USD Thousand)
9.3.7 Japan: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.3.7.1 Japan: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.3.7.2 Japan: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)
9.3.7.3 Japan: Neoantigens Market, by Therapeutic Application, 2023–2028 (USD Thousand)
9.3.8 India: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.3.8.1 India: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.3.8.2 India: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)
9.3.8.3 India: Neoantigens Market, by Therapeutic Application, 2023–2028 (USD Thousand)
9.3.9 South Korea: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.3.9.1 South Korea: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.3.9.2 South Korea: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)
9.3.9.3 South Korea: Neoantigens Market, by Therapeutic Application, 2023–2028 (USD Thousand)
9.3.10 Australia: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.3.10.1 Australia: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.3.10.2 Australia: Neoantigens Market, by Treatment, 2019–2028 (USD Thousand)
9.3.10.3 Australia: Neoantigens Market, by Therapeutic Application, 2023–2028 (USD Thousand)
9.3.11 Rest of Asia-Pacific: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.3.11.1 Rest of Asia-Pacific: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.3.11.2 Rest of Asia-Pacific: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
9.3.11.3 Rest of Asia-Pacific: Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)
9.4 Middle East and Africa: Neoantigens Market
9.4.1 Overview
9.4.2 Middle East and Africa: Neoantigens Market - Revenue and Forecast to 2028 (USD Thousand)
9.4.3 Middle East and Africa: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)
9.4.4 Middle East and Africa: Equipment Market, by Therapeutic Specialty, 2023–2028 (USD Thousand)
9.4.5 Middle East and Africa: Neoantigens Market, by Country, 2020& 2028 (%)
9.4.6 UAE: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.4.6.1 UAE: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.4.6.2 UAE: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)
9.4.6.3 UAE: Equipment Market, by Therapeutic Specialty, 2023–2028 (USD Thousand)
9.4.7 Saudi Arabia: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.4.7.1 Saudi Arabia: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.4.7.2 Saudi Arabia: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)
9.4.7.3 Saudi Arabia: Equipment Market, by Therapeutic Specialty, 2023–2028 (USD Thousand)
9.4.8 South Africa: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.4.8.1 South Africa: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.4.8.2 South Africa: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)
9.4.8.3 South Africa: Neoantigens Market, by Therapeutic Specialty, 2023–2028 (USD Thousand)
9.4.9 Rest of Middle East and Africa: Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)
9.4.9.1 Rest of Middle East and Africa: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.4.9.2 Rest of Middle East and Africa Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)
9.4.9.3 Rest of Middle East and Africa: Neoantigens Market, by Therapeutic Specialty, 2023–2028 (USD Thousand)
9.5 South and Central America: Neoantigens Market
9.5.1 Overview
9.5.2 South and Central America: Neoantigens Market, by Country, 2023 & 2028 (%)
9.5.3 South and Central America: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)
9.5.4 South and Central America: Neoantigens Market, by Therapeutic Application, 2023–2028 (USD Thousand)
9.5.5 South and Central America: Neoantigens Market, by Country, 2023 & 2028 (%)
9.5.6 Brazil: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.5.6.1 Brazil: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.5.6.2 Brazil: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)
9.5.6.3 Brazil: Neoantigens Market, by Therapeutic Application, 2023–2028 (USD Thousand)
9.5.7 Argentina: Neoantigens Market – Revenue and Forecast to 2027 (USD Thousand)
9.5.7.1 Argentina: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.5.7.2 Argentina: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)
9.5.7.3 Argentina: Neoantigens Market, by Therapeutic Application, 2023–2028 (USD Thousand)
9.5.8 Rest of South and Central America: Neoantigens Market – Revenue and Forecast to 2027 (USD Thousand)
9.5.8.1 Rest of South and Central America: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
9.5.8.2 Rest of South and Central America: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)
9.5.8.3 Rest of South and Central America: Neoantigens Market, by Therapeutic Application, 2023–2028 (USD Thousand)
10. Impact Of COVID-19 Pandemic on Global Neoantigens Market
10.1 North America: Impact Assessment of COVID-19 Pandemic
10.2 Europe: Impact Assessment of COVID-19 Pandemic
10.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
10.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
10.5 South and Central America: Impact Assessment of COVID-19 Pandemic
11. Neoantigens Market–Industry Landscape
12. Company Profiles
12.1 Achilles Therapeutics plc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Advaxis, Inc.
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Frame Cancer Therapeutics
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Genocea
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Gradalis, Inc.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Gritstone Oncology
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Immunicum AB
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Medigene AG
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Ziopharm Oncology, Inc.
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Moderna, Inc.
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About the Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. New Cancer Cases Registered Worldwide, 2020
Table 2. North America: Neoantigens Market, by Treatment – Revenue and Forecast to 2028(USD Thousand)
Table 3. North America: Neoantigens Market, by Therapeutic Specialty – Revenue and Forecast to 2028 (USD Thousand)
Table 4. US: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
Table 5. US: Neoantigens Market, by Therapeutic Specialty – Revenue and Forecast to 2028 (USD Thousand)
Table 6. Canada: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
Table 7. Canada: Neoantigens Market, by Therapeutic Specialty – Revenue and Forecast to 2028 (USD Thousand)
Table 8. Mexico: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
Table 9. Mexico: Neoantigens Market, by Therapeutic Specialty – Revenue and Forecast to 2028 (USD Thousand)
Table 10. Europe: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
Table 11. Europe: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)
Table 12. Incidence, Mortality and Prevalence by cancer site, 2020, Germany
Table 13. Germany: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
Table 14. Germany: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)
Table 15. Incidence, Mortality and Prevalence by cancer site, 2020, France
Table 16. France: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
Table 17. France: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)
Table 18. UK: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
Table 19. UK: Neoantigens Market, Application – Revenue and Forecast to 2028 (USD Thousand)
Table 20. Incidence, Mortality and Prevalence by cancer site, 2020, Italy
Table 21. Italy: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
Table 22. Italy: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)
Table 23. Incidence, Mortality and Prevalence by cancer site, 2020, Spain
Table 24. Spain: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
Table 25. Spain: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)
Table 26. Rest of Europe: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
Table 27. Rest of Europe: Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)
Table 28. Asia Pacific Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
Table 29. Asia Pacific Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)
Table 30. China Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
Table 31. China Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)
Table 32. Japan Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
Table 33. Japan Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)
Table 34. India Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
Table 35. India Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)
Table 36. South Korea Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
Table 37. South Korea Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)
Table 38. Incidence, Mortality and Prevalence by Cancer Site, Australia, 2020
Table 39. Australia Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
Table 40. Australia Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)
Table 41. Rest of Asia-Pacific: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
Table 42. Rest of Asia-Pacific: Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)
Table 43. Middle East and Africa Neoantigens Market, by Treatment– Revenue and Forecast to 2028(USD Thousand)
Table 44. Middle East and Africa Equipment Market, by Therapeutic Specialty – Revenue and Forecast to 2028 (USD Thousand)
Table 45. UAE Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
Table 46. UAE Equipment Market, by Therapeutic Specialty – Revenue and Forecast to 2028 (USD Thousand)
Table 47. Saudi Arabia Neoantigens Market, by Treatment– Revenue and Forecast to 2028 (USD Thousand)
Table 48. Saudi Arabia Equipment Market, by Therapeutic Specialty – Revenue and Forecast to 2028 (USD Thousand)
Table 49. South Africa Neoantigens Market, by Treatment– Revenue and Forecast to 2028 (USD Thousand)
Table 50. South Africa Neoantigens Market, by Therapeutic Specialty – Revenue and Forecast to 2028 (USD Thousand)
Table 51. Rest of Middle East and Africa Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
Table 52. Rest of Middle East and Africa Neoantigens Market, by Therapeutic Specialty – Revenue and Forecast to 2028 (USD Thousand)
Table 53. South and Central America Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
Table 54. South and Central America Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)
Table 55. Brazil Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
Table 56. Brazil Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)
Table 57. Argentina Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
Table 58. Argentina Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)
Table 59. Rest of South and Central America Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)
Table 60. Rest of South and Central America Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)
Table 61. Glossary of Terms, Neoantigens Market
LIST OF FIGURES
Figure 1. Neoantigens Market Segmentation
Figure 2. Neoantigens Segmentation, By Region
Figure 3. Global Neoantigens Market Overview
Figure 4. Combination Therapy Segment Holds Largest Share of Neoantigens Market
Figure 5. APAC to Show Remarkable Growth During Forecast Period
Figure 6. Global Neoantigens Market, by Geography (US$ Thousand)
Figure 7. Global Neoantigens Market – Leading Country Markets (US$ Thousand)
Figure 8. Global Neoantigens Market, Industry Landscape
Figure 9. North America: PEST Analysis
Figure 10. Europe: PEST Analysis
Figure 11. Asia Pacific: PEST Analysis
Figure 12. Middle East and Africa: PEST Analysis
Figure 13. South and Central America: PEST Analysis
Figure 14. Expert Opinion
Figure 15. Neoantigens Market Impact Analysis of Drivers and Restraints
Figure 16. Global Neoantigens Market – Revenue Forecast and Analysis – 2023- 2028
Figure 17. Global Neoantigens Market – By Geography Forecast and Analysis – 2020- 2028
Figure 18. Neoantigens Market Revenue Share, by Treatment (2023 and 2028)
Figure 19. Combination Therapy: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)
Figure 20. Mono Therapy: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)
Figure 21. Neoantigens Market Revenue Share, by Therapeutic Specialty (2023 and 2028)
Figure 22. Gastrointestinal Cancer: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)
Figure 23. Lung Cancer: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)
Figure 24. Solid Tumors: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)
Figure 25. Urinary System Cancers: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)
Figure 26. Melanoma: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)
Figure 27. Head and Neck Cancers: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)
Figure 28. Others: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)
Figure 29. North America: Neoantigens Market, by Key Country – Revenue (2023) (USD Thousand)
Figure 30. North America: Neoantigens Market Revenue and Forecast to 2028 (USD Thousand)
Figure 31. North America: Neoantigens Market, by Country, 2023 & 2028 (%)
Figure 32. US: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 33. Canada: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 34. Mexico: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 35. Europe: Neoantigens Market, by Key Country – Revenue (2023) (USD Thousand)
Figure 36. Europe: Neoantigens Market Revenue and Forecast to 2028 (USD Thousand)
Figure 37. Europe: Neoantigens Market, by Country, 2023 & 2028 (%)
Figure 38. Germany: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 39. France: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 40. UK: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 41. Italy: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 42. Spain: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 43. Rest of Europe: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 44. Asia Pacific: Neoantigens Market, by Key Country – Revenue (2023) (USD Thousand)
Figure 45. Asia Pacific Neoantigens Market Revenue and Forecast to 2028 (USD Thousand)
Figure 46. Asia Pacific: Neoantigens Market, by Country, 2023 & 2028 (%)
Figure 47. China: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 48. Japan: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 49. India: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 50. South Korea: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 51. Australia: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 52. Rest of Asia-Pacific: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 53. Middle East and Africa: Neoantigens Market, by Key Country – Revenue (2023) (USD Thousand)
Figure 54. Middle East and Africa Neoantigens Market Revenue and Forecast to 2028 (USD Thousand)
Figure 55. UAE: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 56. Saudi Arabia: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 57. South Africa: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 58. Rest of Middle East and Africa: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 59. South and Central America: Neoantigens Market, by Key Country – Revenue (2023) (USD Thousand)
Figure 60. South and Central America: Neoantigens Market, by Country, 2023 & 2028 (%)
Figure 61. South and Central America: Neoantigens Market, by Country, 2023 & 2028 (%)
Figure 62. Brazil: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 63. Argentina: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 64. Rest of South and Central America: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 65. Impact of COVID-19 Pandemic in North American Country Markets
Figure 66. Impact of COVID-19 Pandemic in European Country Markets
Figure 67. Impact of COVID-19 Pandemic in Asia Pacific Country Markets
Figure 68. Impact Of COVID-19 Pandemic in Middle East and Africa Market
Figure 69. Impact Of COVID-19 Pandemic in South and Central America Market
The List of Companies - Neoantigens Market
- Achilles Therapeutics plc
- Advaxis, Inc.
- Frame Cancer Therapeutics
- Genocea
- Gradalis, Inc.
- Gritstone Oncology
- Immunicum AB
- Medigene AG
- Ziopharm Oncology, Inc.
- Moderna, Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For